Explain this page
Arphra AIPlain-English read on HCA Healthcare, Inc.’s valuationUpcoming events
Next ex-div
Jun 16, 2026tomorrow
$0.78
06-08today
- Is HCA Undervalued? DCF Says Worth $7654d
- Vizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting6d
- Vizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting6d
- HCA Healthcare, Inc. to Present at May Conference45d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$1,759.73
+354.50% vs spot
Recommendation
Strong Buy
16 of 18 methods
Method spread
9bull7bear
±5% threshold
Analyst PT consensus: $527.45 (+36.23%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.29% | +4.91% | -10.52% | -27.35% | -20.13% | -17.07% | +5.04% | +36.24% | +86.27% | +396.32% | +1148.16% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$24.83M
10 txns
Net flow
−$24.83M
Aftermarket
LiveLast trade
$387.15
707 sh
Bid
$383.38
15 sh
Ask
$392.00
101 sh
Spread
$8.620
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $19.11B | $1.62B | $7.15 |
| Q4 Dec 2025 | $19.51B | $1.88B | $8.14 |
| Q3 Sep 2025 | $19.16B | $1.64B | $6.96 |
| Q2 Jun 2025 | $18.61B | $1.65B | $6.83 |
| Q1 Mar 2025 | $18.32B | $1.61B | $6.45 |
| Q4 Dec 2024 | $18.29B | $1.44B | $5.63 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$527.45
+36.23% upside
Low
$436.00
Median
$530.00
High
$635.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- Is HCA Undervalued? DCF Says Worth $765gurufocus.com·Jun 10, 2026
- Vizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meetingbusinesswire.com·Jun 08, 2026
- Vizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meetingbusinesswire.com·Jun 08, 2026
- HCA Healthcare, Inc. to Present at May Conferencebusinesswire.com·Apr 30, 2026
Recent analyst activity
DB- Jun 04, 2026GradeMarket Perform → Market PerformHCA Healthcare Inc (HCA) PT Lowered to $413 at Bernstein SocGen Amid Policy RisksBernstein
- Jun 04, 2026PT$413.00HCA Healthcare Inc (HCA) PT Lowered to $413 at Bernstein SocGen Amid Policy RisksTruist Financial
- Jun 04, 2026PT$413.00HCA Healthcare price target lowered to $413 from $503 at BernsteinBernstein
Peers
Total assets
$60.72B
Total debt
$50.2B
Cash & equiv
$1.04B
Operating CF
$12.64B
Free cash flow
$7.69B
Buybacks
-$10.07B
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
McAlevey Michael R officer: EVP & Chief Legal & Admin Off. | Sell | 1,694 | $903.54K | Feb 18, 2026 |
Wyatt Christopher F. officer: SVP & Controller | Sell | 4,000 | $2.02M | Feb 11, 2026 |
Berres Jennifer officer: SVP & Chief Human Res. Officer | Sell | 4,010 | $2.02M | Feb 11, 2026 |
Berres Jennifer officer: SVP & Chief Human Res. Officer | Sell | 4,010 | $2.11M | Feb 11, 2026 |
HAZEN SAMUEL N director, officer: CEO | Sell | 5,162 | $2.57M | Feb 03, 2026 |
HAZEN SAMUEL N director, officer: CEO | Sell | 14,716 | $7.4M | Feb 03, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $75.6B | $11.97B | $6.78B | $28.38 | +8.97% |
| FY 2024 | $70.6B | $10.55B | $5.76B | $22.00 | +8.16% |
| FY 2023 | $64.97B | $9.63B | $5.24B | $18.96 | +8.07% |
| FY 2022 | $60.23B | $9.05B | $5.64B | $19.15 | +9.37% |
| FY 2021 | $58.75B | $9.68B | $6.96B | $21.16 | +11.84% |